Study

CBD for Individuals with Mild Cognitive Impairment and at Risk for Alzheimer's Disease

Our study is seeking individuals aged 55-85, who have been diagnosed with Mild Cognitive Impairment (MCI) and are at risk for Alzheimer's Disease. The goal of the study is to see whether cannabidiol (CBD) can improve MCI symptoms.

Why this Research Matters

This study wants to learn if different types of CBD can reduce MCI symptoms like trouble sleeping, memory problems, cognitive dysfunction, anxiety, and inflammation.

What to Expect

You will have a visit to see if you qualify for the study. If you qualify, you will be put into one of three groups. You can’t choose your group. One group will get CBD that has a tiny amount of tetrahydrocannabidiol (THC). The second group will get CBD that has no THC. The third group will get a placebo, which looks like the study drug but has no real medicine in it. At in-person visits, we will take a small amount of blood from your arm, ask you to fill out surveys, and you will do some thinking and memory tests. During phone check-ins, a study team member will ask about any medications you are taking and if you have had any side effects from the study medication.

Study Duration

You will have an in-person visit every 6 weeks and a phone check-in every two weeks for a total of 24 weeks.

Who can Participate

55 to 85 years

You may be able to join the study if you:

Are between the ages of 55-85 years old.
Have been diagnosed with Mild Cognitive Impairment (MCI) after a memory and thinking test.
Have someone that can help you with the study.
Are interested in using CBD to help with memory and thinking.
Plan to live in the Denver metro area for the next 6 months.
Can go to in-person study visits.